Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

B42 Inhibitors

B42 inhibitors represent a distinct class of chemical compounds known for their specific interaction with a particular target enzyme or protein, often involved in intricate biochemical pathways. These inhibitors are characterized by their ability to bind to the active site or an allosteric site of the target molecule, thereby modulating its function. The structural diversity within the B42 inhibitor class allows for a wide range of binding affinities and specificities, which are crucial for their effectiveness in altering the activity of their target enzymes or proteins. The core structure of B42 inhibitors typically includes a heterocyclic ring system that interacts with key residues within the target's active site. Additionally, the inhibitors may feature various substituents that enhance their binding interactions through hydrogen bonding, van der Waals forces, and hydrophobic interactions. The precise geometry and electronic distribution within these molecules are often optimized to achieve maximal interaction with the target while minimizing off-target effects. From a chemical perspective, B42 inhibitors are synthesized through a series of carefully controlled reactions, often involving the formation of key carbon-nitrogen bonds, cyclization reactions, and the introduction of specific functional groups that confer desired physicochemical properties. The synthetic routes are typically designed to ensure high yield and purity, often involving multi-step procedures that require precise control over reaction conditions. The final compounds are usually subjected to rigorous characterization techniques, including nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and X-ray crystallography, to confirm their structure and purity. Additionally, computational modeling and structure-activity relationship (SAR) studies are frequently employed to refine the design of these inhibitors, ensuring that they exhibit the desired interaction profile with their target. The result is a chemically diverse class of inhibitors with finely tuned properties tailored to their specific biochemical roles.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$218.00
$322.00
$426.00
7
(1)

Acts as a DNA methyltransferase inhibitor; can disrupt transcriptional activities, affecting the coactivation functions of PNRC1.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Histone deacetylase inhibitor that may indirectly affect PNRC1 by altering chromatin structure and nuclear receptor binding.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Another histone deacetylase inhibitor that could affect nuclear receptor interactions with PNRC1.

Mithramycin A

18378-89-7sc-200909
1 mg
$55.00
6
(1)

Inhibits SP1 binding to GC-rich DNA; can affect transcriptional regulation, thereby influencing PNRC1 activity.

Geldanamycin

30562-34-6sc-200617B
sc-200617C
sc-200617
sc-200617A
100 µg
500 µg
1 mg
5 mg
$39.00
$59.00
$104.00
$206.00
8
(1)

Hsp90 inhibitor that could disrupt PNRC1's interaction with other proteins in the nucleus.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$186.00
$707.00
88
(1)

Rho kinase (ROCK) inhibitor that may affect nuclear-cytoplasmic shuttling of PNRC1.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$231.00
$863.00
1
(0)

Affects BRD4 bromodomains, potentially interfering with PNRC1 mediated transcription.

GSK 525762A

1260907-17-2sc-490339
sc-490339A
sc-490339B
sc-490339C
sc-490339D
5 mg
10 mg
50 mg
100 mg
1 g
$300.00
$540.00
$940.00
$1680.00
$5900.00
(0)

Another BRD4 inhibitor; alters chromatin state and may influence PNRC1 interaction with nuclear receptors.

A-485

1889279-16-6sc-507493
5 mg
$275.00
(0)

Inhibits p300/CBP, which are general transcription coactivators that may act in concert with PNRC1.

GSK 650394

890842-28-1sc-361201
sc-361201A
10 mg
50 mg
$187.00
$769.00
8
(1)

Serum- and glucocorticoid-induced kinase 1 (SGK1) inhibitor; could influence PNRC1 indirectly through cortisol signaling.